Cyient DLM Ltd Q4 FY26 Earnings Analysis

Published 15 Aug 2026 | Market Cap: ₹5.3K Cr

Price

697

Market Cap

₹5.3K Cr

P/E Ratio

64.3

Earnings Summary

FY '27 expected to deliver strong year-over-year growth across all quarters, recovering from FY '26 softness. FY '27 is expected to see a strong year-over-year growth in revenue, underpinned by a strong order book and a healthy sales pipeline (~$0.5 billion).

📊 Revenue & Sales Performance

  • FY '27 expected to deliver strong year-over-year growth across all quarters, recovering from FY '26 softness.
  • Targeted 25% year-on-year growth for FY '27, aiming around INR 1,600 crores revenue.
  • Strong order intake and pipeline (~$0.5 billion) supporting growth prospects.
  • Investments in sales teams to enhance customer acquisition and order intake; more hires planned in the current quarter.
  • Growth not limited to aerospace & defense; expanding in non-A&D sectors and new verticals like electric vehicles.
  • Altek acquisition expected to contribute positively with quicker order-to-revenue conversion.
  • Build-to-specification engagements anticipated to scale up from FY '27 Q3/Q4 and further in FY '28.
  • No structural challenges; growth depends on having the right sales resources on the ground.
  • Operating leverage expected to improve margins slightly with volume growth.

📈 Profitability & Margins

  • FY '27 is expected to see a strong year-over-year growth in revenue, underpinned by a strong order book and a healthy sales pipeline (~$0.5 billion).
  • Management projects around 25% year-on-year revenue growth for FY '27, targeting roughly INR 1,600 crores in revenue.
  • Operating leverage benefits are anticipated as volumes increase, potentially improving EBITDA margins beyond the current double-digit level (around 10-11%).
  • Altek acquisition growth is expected to contribute positively in FY '27, with synergies starting to materialize gradually.
  • Margins are expected to sustain at double-digit levels, with potential for improvement as scale and cross-business synergies increase.
  • The company is focused on tight control over operating expenses and improving working capital efficiency, which should support profitability.
  • No exact earnings or EPS guidance provided, but management expresses confidence in sustained profitable growth and improving profitability in FY '27 and beyond.

🏗️ Capital Expenditure Plans

  • The company is focused on both organic and inorganic growth opportunities.
  • They continue to look for acquisitions opportunistically, targeting both product expansion and geographic presence.
  • Recent acquisition of Altek had challenges but is still central to the growth strategy.
  • Investments have been made in strengthening the sales team across geographies and industry verticals to increase order intake.
  • No specific capex or strategic investment figures were disclosed.
  • The company is advancing in new product areas including semiconductor equipment manufacturing and AI, indicating potential future investments there.
  • They expect cross-pollination benefits between Indian and U.S. businesses to improve margins once tariff issues are resolved.
  • No concrete guidance on capex spend, but ongoing investments in people and product innovation indicate strategic capital allocation.

💰 Fundraising & Capital Structure

  • The company has fully utilized its IPO proceeds as of March 2025, with the account closed and compliant with the objects defined during the IPO.
  • There is no specific mention of any immediate or planned new fundraising through equity or debt in the latest discussions.
  • The management continues to focus on organic and opportunistic inorganic growth through acquisitions, based on market fit and opportunities.
  • No explicit guidance or plans for raising new debt or equity were disclosed in the presented conversations.

📋 Order Book & Pipeline

  • Current executable order book is strong and solid for FY '27, consisting solely of confirmed purchase orders from customers.
  • Order book typically covers 18-24 months, meaning revenue conversion spans multiple financial years.
  • Order intake percentage between FY '25 and FY '26 recovered to be at or above competitor levels (35%-40% growth).
  • Sales pipeline is robust, with a sales pipeline close to $0.5 billion currently in negotiation.
  • Altek acquisition order book operates with shorter book-to-ship cycles, adding near-term revenue.
  • Management expects order inflows and conversion to revenue to improve starting from next quarter (Q1 FY '27).
  • No intercompany orders; all orders are customer-driven.
  • Some deferrals in execution due to external issues (West Asia war, supply chain delays) but expected to normalize in FY '27.
  • The company is confident of strong order intake translating into revenue growth for FY '27 and beyond.

Key Metrics

Frequently Asked Questions

What were Cyient DLM Ltd Q4 FY26 results?

FY '27 expected to deliver strong year-over-year growth across all quarters, recovering from FY '26 softness. FY '27 is expected to see a strong year-over-year growth in revenue, underpinned by a strong order book and a healthy sales pipeline (~$0.5 billion).

What is Cyient DLM Ltd share price analysis?

Cyient DLM Ltd currently shows a neutral. The stock trades at a P/E of 64.3 with a market cap of ₹5,278 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cyient DLM Ltd planning capital expenditure?

The company is focused on both organic and inorganic growth opportunities. - They continue to look for acquisitions opportunistically, targeting both product expansion and geographic presence. - Recent acquisition of Altek had challenges but is still central to the growth strategy. - Investments have been made in strengthening the sales team across geographies and industry verticals to increase order intake. - No specific capex or strategic investment figures were disclosed. - The company is advancing in new product areas including semiconductor equipment manufacturing and AI, indicating potential future investments there. - They expect cross-pollination benefits between Indian and U.S.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.